Managing anemia in patients with chronic heart failure: what do we know?

Ankur Sandhu¹
Sandeep Soman¹
Michael Hudson²
Anatole Besarab¹

¹Divisions of Nephrology,
²Cardiology, Henry Ford Health System, Detroit, Michigan, USA

Abstract: Anemia is common in patients with chronic heart failure (HF) with an incidence ranging from 4% to 55% depending on the studied population. Several studies have highlighted that the prevalence of anemia increases with worsening heart failure as reflected by New York Heart Association classification. Additionally, several epidemiological studies have highlighted its role as a prognostic marker, linking it to worse outcomes including; malnutrition, increased hospitalizations, refractory heart failure and death. The pathophysiology of anemia is multifactorial and related to various factors including; hemodilution, iron losses from anti-platelet drugs, activation of the inflammatory cascade, urinary losses of erythropoietin and associated renal insufficiency. There are a host of epidemiological studies examining HF outcomes and anemia, but only a few randomized trials addressing this issue. The purpose of this article is to review the literature that examines the interrelationship of anemia and congestive HF, analyzing its etiology, impact on outcomes and also the role of associated kidney disease as well as cardio-renal syndrome both as a marker of morbidity and mortality.

Keywords: anemia, cardio-renal syndrome, heart failure

Background
In the US, heart failure (HF) is a leading cause of hospitalization with an estimated number of 900,000 hospitalizations per annum when HF is the primary diagnosis and 2.6 million when HF is the primary or secondary diagnosis.¹ It is estimated that among these individuals, 4% to 61% have anemia and up to 33% have chronic kidney disease (CKD).²⁻⁹ Variability in the estimated prevalence of anemia is partly attributable to use of different definitions of anemia in individual reports. Most of these patients are over 65 years of age, Medicare eligible, and place a huge economic burden on the health care system, with an estimated annual cost in the US of approximately $40 billion.¹⁰,¹¹

The annual mortality rate of patients suffering from congestive heart failure (CHF) refractory to standard medical treatment exceeds 50%.¹² Furthermore, deaths attributed to HF have increased 145% in the last 2 decades.¹³ This increased mortality, despite advances in medical treatment, points to the importance of identifying factors related to poor outcomes and developing new treatment and prevention modalities.

Coronary artery disease (CAD) and hypertension are the two major risk factors for the development of HF in older persons. Other common etiologies include diabetes mellitus, valvular heart disease—especially aortic stenosis and mitral regurgitation—and nonischemic cardiomyopathies. Frequently, HF in older persons is multifactorial.¹⁴

Older patients with hypertension and echocardiographic left ventricular (LV) hypertrophy had a 2.6-times higher incidence of HF than those with hypertension and...
no LV hypertrophy. LV hypertrophy by electrocardiography (ECG) and diabetes mellitus are also risk factors for the development of HF in older persons. In a 43-month follow up of 2902 patients (926 men and 1976 women) with a mean age of 81 years, HF developed in 27% of patients. Significant independent risk factors for the development of HF were male gender (risk ratio = 1.4), hypertension (risk ratio = 2.5), CAD (risk ratio = 4.0), diabetes mellitus (risk ratio = 1.6), and age (risk ratio = 1.05 for each yearly increase in age). Anemia, HF and kidney function

In a meta-analysis of 16 studies, Smith et al found that 63% of 80,098 patients with HF had some degree of concomitant impaired renal function, and 29% had severe CKD. This is of great clinical relevance because it is well known that renal dysfunction in patients with HF is associated with an increased risk of adverse outcomes. In a study by Hillege et al impaired renal function was found to be an even stronger predictor of mortality than ejection fraction (EF) or New York Heart Association (NYHA) functional class in 1906 patients with HF. The reciprocal relationship also holds true and has been the subject of much interest. Cardiovascular disease (CVD) is a very common comorbidity in patients with CKD or end stage renal disease (ESRD) and is the leading cause of mortality in this patient population. Indeed, HF is the key component of cardiovascular (CV) morbidity and mortality across the entire spectrum of CKD, with a 2-year cumulative probability of 39.5%. In a study of the Medicare population, Foley et al found that 39.9% of patients with CKD also had HF on initial presentation, and another 30.7% developed it over the following year. Not only is HF the most common type of CV disease seen in patients new to ESRD, but according to the US Renal Data System 2007 annual data report, approximately two-thirds of incident dialysis patients develop HF within 3 years.

Not surprisingly, CVD is the leading cause of morbidity and mortality in dialysis patients, affecting more than 50% of this population. As much as 64% of the ESRD population, who are dialysis dependent, have chronic HF, further highlighting the bidirectional relationship of these organs.

Most studies indicate that the prevalence of anemia is increased in patients with HF who also have co-morbid kidney disease, advanced age, and more severe symptoms (range, 30% to 61%) when compared with less symptomatic ambulatory populations (range, 4% to 23%). In patients with HF and preserved ejection fraction, the few published reports indicate that anemia is also highly prevalent in this group. Anemia and cardiovascular disease

The World Health Organization defines anemia as a hemoglobin count less than 13 g/dL in men and 12 g/dL in women. If this definition were to be used, anemia is common in patients with HF. Additionally, anemia is common in patients with a glomerular filtration rate (GFR) of less than 60 mL/min, with increasing prevalence noted with declining GFR (see Figure 2).

As stated previously, CVD is widely prevalent in patients with CKD and more so in dialysis populations. Over half of the patients who are end stage renal disease-dialysis dependent (ESRD-DD) will die of CVD and its sequelae. Parfrey et al reported that around 74% patients have left ventricular hypertrophy (LVH), 32% left ventricular dilatation and 15% systolic dysfunction on initiation of renal replacement therapy (RRT). In those on RRT, the incidence of de novo ischemic heart disease is 5% and of HF 11% per year of RRT. Of key importance is the finding that having both HF and LVH predicts poorer survival in these patient populations. Levin et al looked at pre-dialysis CKD populations and noted that both hemoglobin levels and systolic blood pressure were associated with LVH. Interestingly, Levin et al also showed that the presence of anemia...
Figure 1 Schematic diagram showing how anemia causes fluid retention and heart failure which in turn reduced renal perfusion and produces renal dysfunction. Based on studies.58,63,88,89,100,101

Abbreviations: BUN, blood urea nitrogen; CHF, congestive heart failure; GFR, glomerular filtration rate; LVH, left ventricular hypertrophy.

Figure 2 Relationships of the frequency and severity of anemia in a chronic kidney disease population. As renal function worsens, the fraction of subjects with hematocrit <33% increases 3-fold, from 24% to 74%. Drawn from data of Kazmi et al.18
and CVD was associated with a reduced time needed for the initiation of dialysis. The impact of anemia, CKD, and HF on mortality was assessed in a Medicare sample population as shown in Figure 3. The presence of CKD or HF increased the likelihood of death 2- to 2.5-fold over having neither. Anemia increased the likelihood of death to almost 4 with either covariate. Having all three increased the likelihood of death 6-fold.

**Pathophysiology of anemia in chronic heart failure**

The etiology and pathophysiology of anemia in HF is multifactorial. Androne et al reviewed 196 advanced heart failure patients with anemia, 46% experienced anemia from hemodilution due to expansion of plasma volume rather than a true reduction in red blood cell mass, with only 54% experiencing “true anemia”. Other mechanisms of anemia are associated with chronic disease, iron losses due to anti-platelet drugs and anticoagulants as well as urinary losses of serum erythropoietin (EPO) and transferrin.

HF itself can be considered to produce an inflammatory milieu, in which inflammatory cytokines such as interleukins 1, 6, 18 and tumor necrosis factor alpha (TNF-α) are noted to be elevated. Higher levels of TNF-α are found in the circulation and in the myocardium of patients with chronic heart failure as compared to controls. TNF-α has been implicated in a number of pathophysiological processes that are thought to be important in the progression of chronic heart failure. Patients with NYHA class IV symptoms, those with cardiac cachexia and those with edematous decompensation of their disease have the highest serum TNF-α levels. These inflammatory cytokines have been reported to cause anemia in vitro. Cytokine-mediated responses include reduced red blood cell progenitor proliferation, with erythropoietin blunting, hepcidin elevation with resultant stunted iron absorption at the level of the intestine and the blockade of iron release from macrophages. These inhibitory effects of TNF alpha are shown schematically in Figure 4.

Both ACE inhibitors and long-term aspirin use have also been implicated in the anemia related to HF. The SOLVD trial showed a significantly higher prevalence of anemia in the Enalapril arm compared with placebo (11.3% vs 7.9%, OR 1.56). The authors hypothesized that ACE inhibitors inhibit erythroid precursor cells. Angiotensin II is a growth factor and ACE inhibitors lead to the formation of a tetrapeptide (N-acetyl-seryl-lysyl-proline or AcsSDKP) which is an endogenous inhibitor of erythropoiesis. This property of ACE inhibitors to inhibit erythrocytosis is used therapeutically in polycytemic patients and in the setting

---

**Figure 3** Likelihood for death before end stage renal disease during 2-year of follow-up in Medicare 5% sample: 1996–1997, aged ≥65 on 1/1/96. Odds ratios adjusted for age, gender, and race. ICD 9 codes for anemia 280.xx through 285.xx. Note how the likelihood of death increases as anemia, CKD, and CHF are combined as comorbid conditions. Drawn from data of Collins et al.

**Abbreviations:** CHF, congestive heart failure; CKD, chronic kidney disease; DM, diabetes.
Anemia from long-term Aspirin use is thought to be related to masked gastrointestinal blood losses. Other contributing factors in the pathogenesis of anemia include phlebotomy, the induction of a ferropenic state and EPO resistance which is thought to increase with HF severity. Serum erythropoietin levels and HF

EPO levels have been shown to be elevated in HF. Volpe et al noted that plasma EPO levels increased with worsening NYHA classification, the exact significance of this finding is not fully understood but could be a physiological response to increasing anemia as HF worsened.52 In a Netherlands study, Van der Meer and colleagues retrospectively examined 74 Caucasian patients with mild to advanced HF. During the mean follow up of 3 years they found that anemia was present in 24% of patients, and that increased plasma EPO levels were associated with increased mortality, independent of hemoglobin levels. Interestingly, they also noted that in HF patients, EPO levels did not correlate with the hemoglobin levels.53 This lack of a quantitative relationship in the degree of anemia, as reflected by hemoglobin and EPO levels in HF, is paralleled by a similar observation in patients with varying stages of CKD.54 Evidently the effect of circulating inflammatory cytokines at multiple sites, including EPO production as well as the erythropoietic action of EPO in the bone marrow, interferes with the normal operation of the feedback system so that it produces an inverse relationship of hemoglobin to EPO levels.

The spectrum of cardio-renal syndrome

The generic definition of CRS is used to describe an acute decline in kidney function in patients with decompensated heart failure. The pathophysiology in organ discordance is still largely poorly understood but is thought to be related to a complex interplay between a structurally failing heart, sympathetic, neurohumoral and inflammatory mediators resulting in renal vasoconstriction with ischemia contributing in a reduced GFR. However, many have argued that this definition is too simplistic, ambiguous and lacked widespread uniformity causing confusion.7,24,49,55 Ronco et al argued that communication of both organs was indeed “bi-directional”, where one organ, whether heart or kidney, could lead to the dysfunction of the other. With this thought process in mind, Ronco proposed a classification system that would take into account the chronology of the initial organ failure and the pathophysiological coping communication interplay that ensues. Ronco et al classified CRS into 5 subtypes, giving CRS some degree of uniformity.25–27

• CRS type 1 (acute CRS): characterized by a rapid worsening of cardiac function, leading to acute kidney injury (AKI). This is thought to be the most common type with AKI conferring the worst prognosis.
• CRS type 2 (chronic CRS): characterized by chronic abnormalities in cardiac function (eg, chronic congestive HF) causing progressive CKD, thus measuring serum creatinine in this setting can often be misleading.
• CRS type 3 (acute renocardiac syndrome): characterized by an abrupt and primary worsening of kidney function (eg, AKI, ischemia, or glomerulonephritis).
• CRS type 4 (chronic renocardiac syndrome): characterized by a condition of primary CKD (eg, chronic glomerular disease).
• CRS type 5 (secondary CRS): characterized by the presence of combined cardiac and renal dysfunction due to acute or chronic systemic disorders.

The pathophysiology of worsening renal function in CRS is depicted in Figure 5.
Why is CRS important?

The Analysis of the Acute Decompensated Heart Failure National Registry (ADHERE) was set up in part to address this question.\textsuperscript{56,57} The results showed that the risk of inpatient mortality was significantly increased if patients exhibited the following: a blood urea nitrogen (BUN) of greater than 42 mg/dL; serum sodium less than 134 mmol/L, creatinine greater than 3.2 mg/dL, an age greater than 78, dyspnea at rest, systolic blood pressures less than 115 mmHg and diastolic readings less than 55 mmHg (Table 1). The main limitation of ADHERE is that the study was retrospective, the data observational, and thus the relationships are associative and not necessarily causal.\textsuperscript{56} In 2006, Smith et al reviewed and conducted a metaanalysis of 16 studies that looked at more than 80,000 patients with HF. They found after a 1 year follow up mortality was significantly higher in patients with moderate to severe renal impairment, compared with those with normal kidney function or even mild impairment.\textsuperscript{2} Furthermore, impaired renal function is consistently found as an independent predictor for 1 year mortality in acute heart failure patients. An elevated BUN even without a reduction in GFR was highlighted as a poor prognostic marker by Aronson et al, a finding substantiated in the ACTIV in CHF study.\textsuperscript{58,59} This paradoxical finding is thought to be secondary to renal hypoperfusion contributing to pre-renal azotemia. Silva and colleagues explored this further and noted that both an increased serum creatinine and a low ejection fraction (EF) were associated with increased death, a finding also supported by Dries et al\textsuperscript{60} In a large scale study, Gottlieb et al showed that a serum creatinine increase

![Pathophysiology of worsening renal function in cardio-renal syndrome.](https://www.dovepress.com/)


Abbreviation: CKD, chronic kidney disease.
of greater than 0.3 mg/dL from baseline had a specificity of 81% in predicting inpatient hospital mortality.61

**Associations between cardiorenal syndrome and anemia**

For many years the existence of anemia with CRS was widely ignored, but more recently its role as a prognosticator for morbidity and mortality has been elucidated. The importance of anemia as a risk factor for progressive HF was highlighted as far back as 1987 in the Framingham Study.62 Anemia has been revisited more recently as an independent predictor of mortality, although with inconsistent results. The true prevalence of anemia in CRS is variable, depending upon the studied population, ranging anywhere from 4% to 55%, with increased incidence noted with worsening NYHA classification, and approaching 79% in those with NYHA class IV.3,28,48,63-65

**Anemia as a predictor of morbidity and mortality**

Anemia has been associated with worsening structural heart disease; diastolic dysfunction, LVH, increased left ventricular mass index and higher pulmonary heart pressures. Clinically, anemia is associated with worsening symptoms, increased diuretic use, medically refractory heart failure and reduced mixed venous oxygen saturation, and contributes to “cardiac cachexia” and is associated with increased hospitalizations46 and re-hospitalizations.67 Small studies, often observational have indicated that the presence of and severity of anemia can worsen an NYHA classification in those with HF. These findings have been championed by Silverberg and colleagues. Their observations have prompted more rigorous attention to be paid to anemia correction and management.

In the SOLVD trial, low hemoglobin was found to be an independent predictor of mortality at a mean follow up of 33 months (see Figure 6), with a higher mortality associated with a hematocrit (Hct) of less than 35 (34%) compared with Hct greater than 40 (22%).56 Survival rates steadily declined with each decrease in hemoglobin deciles, with no evidence of a U-shaped relationship.64 Silverberg and colleagues have shown repeatedly that the presence of anemia in HF is associated with increased mortality (see Figure 7).3,28,63

This has been further verified by Kosiborod et al, who looked at 2281 patients that were admitted with a diagnosis of HF between 1994 and 1995. In both adjusted and non adjusted analysis, serum Hct remained an independent predictor of 1 year mortality, – with increased mortality in patients with Hct <27% compared to those with >42%. They also noted that patients with EF ≤ 20% had higher mortality at one year compared with patients with EF ≥ 40% (hazard ratio [HR] = 1.50; 95% confidence interval [CI] 1.20 to 1.86; P = 0.0001). Not surprisingly, patients with a low hemoglobin had a higher rate of re-admissions, with 2% associated increased risk with each 1% drop in Hct (HR 1.02; 95% CI 1.01 to 1.03; P = 0.0002).68

In 2002, Horwich and colleagues, evaluated a cohort of 1061 patients with NYHA class III–IV, with an EF < 40%. They divided patients into 4 groups: those with a hemoglobin <12.3 g/dL, hemoglobin 12.3 to 13.6 g/dL, hemoglobin 13.7 to 14.8 g/dL and with hemoglobin >14.8 g/dL. They found that patients in the lower hemoglobin quartiles were more likely to have HF class IV (P = 0.0001); increased survival was noted in the higher hemoglobin quartile. On multivariate analysis they found that hemoglobin acts as an independent predictor for 1-year mortality with mortality increasing as hemoglobin decreased below 14 g/dL (Figure 7).64 Ezekowitz and coworkers simply dichotomized 12,065 patients with new onset HF into those with or without anemia as defined by the lower limits of normal by gender. After adjustment for clinical and demographic variables, patients with anemia were more likely to be older (odds ratio [OR] 1.01 per year) and female (OR 1.2 [95% confidence interval 1.1 to 1.3]) and to have a history of chronic renal insufficiency (OR = 3.2; 95% CI 2.8 to 3.6), or hypertension (OR 1.3; 95% CI 1.2 to 1.5). Hazard ratios for mortality, adjusting for covariates, were 1.34 (1.24 to 1.46) in anemic patients, and 1.36 (1.23 to 1.50) in those patients with anemia of chronic disease. An absolute difference of 15 percentage points in survival developed within 1 year (75 vs 60%) in non-anemic compared anemic patients, a difference maintained for the next 4 years (see Figure 8).69

---

**Table I Predictors of inpatient mortality in patients with decompensated heart failure**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Died (n = 2675)</th>
<th>Survived (n = 62,505)</th>
<th>OR of death (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt; 78 vs ≤ 78</td>
<td>1.88 (1.74–2.04)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUN &gt; 42 vs ≤ 42</td>
<td>3.34 (3.08–3.62)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cr &gt; 3.2 vs ≤ 3.2</td>
<td>1.99 (1.78–2.24)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP ≤ 115 vs &gt; 115</td>
<td>3.09 (2.85–3.35)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DBP ≤ 55 vs &gt; 55</td>
<td>2.87 (2.62–3.14)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium ≤ 134 vs &gt; 134</td>
<td>2.26 (2.08–2.47)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea at rest n (%)</td>
<td>1220 (46%)</td>
<td>21,757 (35%)</td>
<td>1.57 (1.45–1.70)</td>
</tr>
</tbody>
</table>

From data of Abraham et al.3,66

**Abbreviations:** BUN, blood urea nitrogen; CI, confidence interval; Cr, serum creatine; OR, odds ratio; DBP, diastolic blood pressure; SBP, systolic blood pressure.

Dovepress

**Vascular Health and Risk Management** downloaded from https://www.dovepress.com/ by 54.191.40.80 on 03-Apr-2017

For personal use only.
Figure 6 Post-hoc analysis of the influence of severity of anemia on survival of patients in the SOLVD clinical trial. Drawn from data of Horwich et al.64

Figure 7 One-year mortality rates in a cohort of heart failure patients by deciles of hemoglobin level. Drawn from data of Horwich et al.64
analysis of Studies of LV Dysfunction (SOLVD) database, evaluation of the interaction between the level of Hct and the level of GFR on all-cause mortality suggests that anemia and reduction in kidney function are more than additive as risk factors. In fact, the relative risk of death rises with a drop in Hct for each level of GFR (see Figure 9).

In the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study, hemoglobin levels were noted to be an independent risk factor for death and re-hospitalization with every 1 g/dL drop in hemoglobin. Szachniewicz and colleagues conducted a prospective study looking at 176 patients; their primary endpoint was to determine the all-cause mortality. They noted, as with other studies, that patients with symptomatic HF as evidenced by a worsening NYHA classification had lower hemoglobin levels. On Kaplan-Meier survival curves they found that the 18-month survival in HF patients with anemia was clinically significant compared with those with normal hemoglobin levels. The PRAISE study, was a prospective multi-center study, that evaluated in 1130 patients the associations of EF < 30%, NYHA classification functional class IIIB or IV, and baseline Hct to the most important outcome, patient mortality. The findings indicated that anemia was an independent predictor for mortality in patients with severe HF. Patients with Hct of 25.4% to 37.5%, were noted to have worse mortality, and every 1% decrease in Hct was associated with a 11% higher risk of mortality. A recent meta-analysis of 34 studies describing HF and anemia by Groenveld and others, identified 153,180 HF patients of whom 37.2% were anemic (see Figure 10). After a minimal follow-up of 6 months, 46.8% of anemic patients had died compared with 29.5% of non-anemic patients. Crude mortality risk of anemia had an odds ratio of 1.96 (95% CI 1.74 to 2.21; \( P < 0.001 \)). Lower baseline hemoglobin values were associated with increased crude mortality rates (\( r = -0.396; P < 0.025 \)). Adjusted hazard ratios showed an increased adjusted risk for anemia (HR 1.46; 95% CI 1.26 to 1.69; \( P = 0.001 \)). Subgroup analysis showed no significant difference between mortality risk of anemia in diastolic or systolic HF.

Whether or not the effect of anemia is truly a directly independent effect cannot be readily determined by such associative studies since both anemia and degree of HF may be due to other variables, particularly co-morbid conditions which then create pitfalls in interpreting current observational studies examining anemia and HF. Many studies have postulated a causal relationship between anemia and HF without adjusting for other co-morbidities, making data analysis questionable. To examine for such a possibility, Kalra

Figure 8 Survival of heart failure patients with and without anemia at the time of initial diagnosis of heart failure.

Note: Survival curves were generated using Kaplan-Meier methods (\( P < 0.0001 \) for anemia present versus anemia absent).

Drawn from data of Ezekowitz et al. 2003.
Figure 9 Survival of heart failure patients by level of glomerular filtration rate and hematocrit.

Notes: GFR in mL/min/1.73 m².
Drawn from data of Al-Ahmad et al. 2001.10

Figure 10 Relationship between baseline hemoglobin and annual mortality in patients with heart failure.

Notes: The area of each circle is proportional to the sample size in each cohort. The center line shows the estimated mortality risk per year of lower baseline hemoglobin values on a continuous scale. The dotted lines represent 95% confidence intervals.
Drawn from data of Groenveld et al. 2008.73
et al studied 552 patients with new onset HF, although they found a significant increase in the incidence of anemia they did not find it to be an independent covariate for worsening outcomes when they adjusted for other variables, specifically co-morbidities.  

Anemia, CKD and HF

Such confounding results are also present in studies of HF complicated by the presence of CKD and anemia. In a retrospective analysis by McClellan et al who looked at 755 patients, who were discharged from community hospitals, with a diagnosis of heart failure. They found that the 1-year death rate with patients with and without a diagnosis of CKD were 44.9% and 34.1%, respectively (relative risk 1.43; 95% CI 1.17 to 1.75). An Hct was recorded for 633 patients, with increasing prevalence of anemia with CKD, the anemia being of greater severity with worsening GFR. Strikingly, they found the one year mortality to be 31.2% in patients with an admission Hct of ≥ 40% and 50% in those with an admission Hct of 30% to 35%. After multivariate analysis they concluded that both hematocrit and serum creatinine were independently associated with increased mortality. Unfortunately, the investigators had to use admission Hct which could have been confounded by varying degrees of hemodilution. Herzog et al examined a cohort of 1,136,201 patients using the 5% general Medicare data base, who were enrolled in both Medicare Part A and Part B. To decipher whether anemia itself was an independent risk factor, they applied co-morbidity-adjusted relative risks to each disease state. They noted that patients with both CKD and HF were 3.3 times more likely to die as compared to the reference population, additionally, they showed that there was a 4-fold increased probability of death if a patient exhibited anemia, CKD and HF. They found that both anemia and CKD served as independent mortality risk factors in the elderly population (see Figure 3). One criticism of this large cohort study is that it shows only associations between disease states and these correlations should not be misinterpreted as “cause and effect.”

Educating care providers

Despite these observations, anemia in both HF and CRS is under treated and under recognized. Silverberg et al writing in the Dialysis Times, refer to data obtained in the Cleveland clinic looking at 2011 ambulatory patients with HF; it was estimated that anemia was only recognized in 11.1% of patients and that only a disappointing 10% of those diagnosed with anemia were treated for their anemia. The treatment and management of anemia in CRS requires a multidisciplinary approach in addition to educating internists, cardiologists and hematologists alike. Silverberg et al noted an 8-fold increase in anemia referral to nephrologists after in hospital meetings with cardiologists, hematologists and internists.  

Treatment of anemia and correction of cardiac disease

In HF small differences in hemoglobin are associated with worse outcomes and symptoms. Correction and management of anemia have been shown to improve NYHA classification, LVEF, LVH and diuretic response in some small studies. Additionally, in some small studies better outcomes and reduced rates of re-hospitalization occur after anemia treatment. Yet, anemia treatment and management in HF are controversial, partly because anemia is under recognized and diagnosed and there is no consensus as to when to begin therapy or which agents to use. Treatment and management has centered on erythropoietin-stimulating agents (ESAs) and parenteral iron supplementation. Unfortunately, most studies are small, non-randomized or blinded, and consequently poorly powered, limiting their validity. In a study of 37 patients with CHF, iron-deficiency anemia was confirmed by bone marrow aspiration in 27 patients (73%), 2 patients (5.4%) had dilutional anemia, and 1 patient (2.7%) had drug-induced anemia. No specific cause was identified in 7 patients (18.9%) who were considered to have “anemia of chronic disease.” Serum ferritin for the iron-deficient patients was not a reliable marker of iron deficiency in this population. Thus, the authors concluded that in this group of patients, iron deficiency was the most common cause of anemia. The iron status of patients with end-stage chronic CHF should be thoroughly evaluated and corrected before considering any other therapeutic interventions. 

Silverberg and colleagues examined the benefits in correcting anemia using a combination of intravenous iron (iron sucrose) and ESAs in the form of subcutaneous EPO. They randomized patients with severe HF (NYHA class III–IV) with hemoglobin levels of 10 to 11.5 g/dL into 2 groups, a control group (no anemia correction, 16 patients) and a treatment group (16 patients, receiving EPO and intravenous iron to correct hemoglobin >12.5 g/dL). They noted that with anemia correction diuretic response, in patient hospital stay, EF, serum creatinine and ferritin improved. The required dose of diuretics targeting the loop of Henle was markedly decreased. Although, ESAs have been noted to produce worsening hypertension, at least theoretically, this is not a finding that was substantiated by the treated arm. In another
larger study, Silverberg and colleagues enrolled 126 anemic HF patients with NYHA class III–IV, with hemoglobin <11.5 g/dL. They noted a marked improvement in NYHA classification, LVEF and shortness of breath and fatigue as measured by a visual analogue scale and a significant reduction in the number of hospitalizations after anemia correction.\textsuperscript{63,81} Additionally, serum creatinine remained unchanged, and NYHA HF staging improved by 1 full grade (see Table 2). The effects of ESAs on hypertension were inconsequential.\textsuperscript{83} A single-blind, placebo-controlled, randomized trial by Mancini et al evaluated the effect of 3 months of ESAs (EPO) treatment on the exercise capacity in 26 patients with NYHA functional class III–IV. They demonstrated that the ESA-treated group had significantly improved their peak oxygen consumption.\textsuperscript{83} Unfortunately, these studies are limited by their small sample size, with a need for larger studies to substantiate their validity and applicability. Van Der Meer and colleagues explored this further through a meta-analysis. They identified 7 randomized controlled studies with 650 HF patients of which 363 were treated with ESAs and 297 with placebo. All patients identified were in NYHA II or III, in all but one study patients had Hct of < 40%. They found that patients treated with ESAs had a 47% reduction in HF related hospitalizations. They did not find a difference in mortality between the two groups, or any increase in rate of hypertension or venous thrombosis in the ESAs treated arms,\textsuperscript{83} but the sample size may have still been too small.\textsuperscript{83} Silverberg reported on an analysis of 10 RCTs. These studies succeeded in raising mean hemoglobin to 12 to 13 g/dL, with no adverse effects and some benefits. The use of ESAs with oral or intravenous iron (in controlled and uncontrolled studies) has been associated with significant improvements in exercise capacity, oxygen utilization, LVEF, LVH and dilution, NYHA classification, BNP, renal function, fatigue, caloric intake and overall quality of life.\textsuperscript{84}

Although these analyses are thought provoking, there is a need for a large powered randomized phase III trial. The STAMINA-HeFT study, a double-blind randomized, placebo controlled, multi-center trial, was set up to examine the effect of an ESA, darbepoetin alpha (DA) treatment on exercise tolerance; secondary endpoints included the effects of anemia treatment by DA on clinical symptoms and outcomes. The study duration was 8 months, enrolling a total of 319 patients: 157 randomized to placebo and 162 to the DA arm. At baseline the median hemoglobin was 11.4 g/dL. By week 12, the median hemoglobin in the DA-treated group had increased by 1.8 g/dL compared to 0.3 g/dL for placebo ($P < 0.0001$). Intent to treat analysis showed that DA did not significantly improve exercise duration, NYHA class, or quality of life score compared with the placebo group. A non-significant trend was observed toward a lower risk of all-cause mortality or first HF hospitalization in DA treated patients compared with placebo (HR 0.68; 95% CI 0.43, 1.08; $P = 0.10$).\textsuperscript{85} Similar findings were noted in a separate controlled trial of darbepoetin with 173 patients.\textsuperscript{86} It should be noted that in these two studies, no differences occurred in mortality or in the incidence of hypertension, venous thrombosis, pulmonary embolus, cerebrovascular disorder, myocardial infarction or other cardiovascular events. Data are awaited from the ongoing Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF) study, a double-blind, multi-centered, placebo-controlled trial of darbepoetin in anemic HF patients which now includes over a thousand patients treated for 6 to 18 months and has a hemoglobin target of 13 g/dL.\textsuperscript{87}

The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) is an ongoing randomized, double-blind, multicenter trial designed to determine the impact of anemia therapy on mortality and CVD in patients with CKD and type 2 diabetes. The trial enrolled over 4000 patients, randomized to achieve target hemoglobin of 13 g/dL or ≥9 g/dL with DA therapy. Placebo was being given as “salvage” therapy for a hemoglobin of < 9 g/dL in the low-hemoglobin group. The primary outcome is a composite endpoint of death, myocardial infarction, acute myocardial ischemia, CHF, and stroke. The TREAT trial may provide critical guidance for the future management of anemia in this high cardiovascular-risk

| Table 2 | Values before and after treatment of anemia in 126 consecutive HF patients |
|-----------------|-----------------|-----------------|-----------------|
| **Before** | **After** | **Before** | **After** |
| Hemoglobin (g/dL) | 10.3 ± 1.3\textsuperscript{a} | 11.3 ± 1.3\textsuperscript{a} | 10.3 ± 1.3\textsuperscript{a} | 11.3 ± 1.3\textsuperscript{a} |
| Hematocrit (%) | 30.6 ± 4.1 | 41.8 ± 32.3\textsuperscript{a} | 30.6 ± 4.1 | 41.8 ± 32.3\textsuperscript{a} |
| Serum creatinine (mg/dL) | 2.4 ± 1.1 | 2.3 ± 1.2 | 2.4 ± 1.1 | 2.3 ± 1.2 |
| ∆ in GFR (mL/min/month) | -0.95 ± 1.19 | 0.27 ± 1.39\textsuperscript{a} | -0.95 ± 1.19 | 0.27 ± 1.39\textsuperscript{a} |
| NYHA (0–4) | 3.8 ± 0.3 | 2.7 ± 0.6\textsuperscript{a} | 3.8 ± 0.3 | 2.7 ± 0.6\textsuperscript{a} |
| Ejection fraction | 33.2 ± 0.3 | 39.6 ± 11.1\textsuperscript{a} | 33.2 ± 0.3 | 39.6 ± 11.1\textsuperscript{a} |
| Fatigue/SOB index (0–10) | 8.9 ± 1.4 | 2.7 ± 1.9\textsuperscript{a} | 8.9 ± 1.4 | 2.7 ± 1.9\textsuperscript{a} |
| Hospitalizations (n) | 3.7 ± 3.5 | 0.2 ± 0.5\textsuperscript{a} | 3.7 ± 3.5 | 0.2 ± 0.5\textsuperscript{a} |
| SBP | 132 ± 22.2 | 131.6 ± 27.9 | 132 ± 22.2 | 131.6 ± 27.9 |
| DBP | 75.2 ± 11.7 | 76.2 ± 11.8 | 75.2 ± 11.7 | 76.2 ± 11.8 |

\textsuperscript{a}At least $P < 0.05$. |
population and the impact of hemoglobin on development of HF and its outcomes. \(^8^8\)

What might the mechanisms be for any salutary effect of erythropoietin in HF over and above increasing hemoglobin? The potentially beneficial effects of EPO in HF include reduced apoptosis of myocytes, reduced cardiac fibrosis, and reduced secretion of inflammatory mediators, a positive anti-oxidant effect, and neovascularization. The last-named effect has been demonstrated in a rat model of myocardial infarction. \(^8^9\)

During EPO therapy it is important to avoid iron deficiency. Three studies, 2 uncontrolled \(^9^0,9^1\) and 1 double-blind, placebo-controlled study \(^9^2\) have shown improved hemoglobin, LVEF, NYHA class, LVH and dilation, reduced heart rate and pulmonary artery pressure with iron treatment alone. In addition, they demonstrated improved quality of life, exercise capacity, renal function, BNP, CRP and hospitalization. The higher the dose of intravenous iron given the greater was the hemoglobin response. These studies suggest that iron deficiency may also play a key role in the anemia of HF. Large controlled studies on this subject are currently in progress.

**Is there an optimal hemoglobin level?**

The only peer-reviewed HF recommendations that refer to anemia in HF, as outlined by the Canadian cardiovascular society in 2007, suggests treating any correctable causes of anemia (iron, vitamin B12, folate). It also states that currently there are insufficient data on routine use of ESA in the treatment of anemia and HF. However, blood transfusions and/or ESAs may be considered if the hemoglobin is less than 9 g/dL and after correction of known factors (iron deficiency, vitamin B12, folate) for symptomatic HF. \(^9^3\) In routine practice, the answer to this question is mostly expert opinion based, with many cardiologists advocating a transfusion threshold to maintain an Hct of \(\geq 30\%\). This recommendation has been chiefly espoused by Herbert et al who noted that, in elderly patients suffering from acute myocardial infarction and angina, who presented on admission a Hct < 30%, had better survival outcomes at 30 days if they were transfused. \(^9^4\) On the other hand, blood transfusion in the setting of acute coronary syndromes was associated with higher mortality, and this relationship persisted after adjustment for other predictive factors and timing of events in a retrospective cohort analysis of prospectively collected clinical trial data. \(^9^5\) In this study, the median baseline and nadir Hct measurements for patients who received a transfusion were 39.9% and 29.0%, respectively, and for patients who did not receive blood, the values were 41.7% and 37.6%, respectively. \(^9^5\)

In the Normal Hematocrit Treatment trial, Besarab et al randomly assigned 1233 hemodialysis patients to Hct targets of either 30% or 42%. Unfortunately, the trial was prematurely stopped for a statistically significant excess of vascular access thrombosis, with a non-significant increase in primary end points, namely non-fatal myocardial infarctions and death in the 42% Hct group. \(^9^6\) Later came the Open Label Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) study, which randomly assigned 1432 CKD patients to either hemoglobin targets of 11.3 g/dL or higher values of 13.5 g/dL. There was a significantly higher rate of primary outcome events, namely myocardial infarction, stroke, HF hospitalization and death in the normal hemoglobin group. \(^9^7\) Paradoxically a subsequent analysis indicated that it was not just the hemoglobin per se, but the inability to respond to increasing doses of EPO that predicted worse outcomes. \(^9^8\) Individuals administered progressively larger doses of ESA and those who could not attain the targeted hemoglobin of 13.3 were the ones at risk for morbidity and mortality. Our take home lesson should be that ESA resistance should not be treated with increases in ESA alone.

**Conclusion**

Anemia in the setting of HF is debilitating, fraught with severe morbidity and mortality in an ever-aging population. Many studies have highlighted the ominous implications of leaving this problem unresolved. Just as internists are recognizing the benefits in improving mortality and morbidity in early CKD referral, internists and cardiologists should be educated to recognize the hallmark of anemia as its management may make a difference in HF outcomes. This underpins the need for better system based practices that need to evolve beyond pharmacological methods tackling HF and should include anemia management.

None of the HF clinical practice guidelines from the US or Europe currently discuss the assessment and management of anemia in HF. Given current evidence, the use of ESA and supplemental iron should only be considered in patients with concomitant CKD or in the management of anemia (hemoglobin < 9 g/dL) with severe symptomatic heart failure, after iron, vitamin B12 and folate replacement. The National Kidney Foundation KDOQI™ clinical practice guideline were updated in 2007 after publication of the CREATE and CHOIR trials and recommended the use of ESA to achieve a hemoglobin target in the range of only 11.0 to 12.0 g/dL. \(^9^9\) With the removal of the quality of life claim by the Food and Drug Administration, the only claim for the use of ESA is to improve quality of life measures such as exercise tolerance...
and functional ability of CKD patients. In HF patients, even these quality of life measures have not been convincingly shown to improve. Therefore, until data from long-term clinical studies are available for HF patients with anemia, the use of ESA is not recommended in anemic patients with HF who do not have a CKD indication for its use.

Anemia is a common co-morbidity in patients with HF and is associated with worse long-term outcomes. Although the cause of anemia in HF is unclear, the weight of evidence suggests that renal dysfunction and neurohumoral and pro-inflammatory cytokine activation in HF favor the development of anemia. Similarly, the mechanisms by which anemia worsens HF outcomes are unknown but may be related to increased myocardial workload. Although anemia is a rational therapeutic target to improve outcomes, there are as yet no convincing data on the efficacy and long-term safety of ESA. Further studies are required to understand the basis of the remarkable association of anemia with HF outcomes, to assess prospectively the potential benefit of correcting anemia, to evaluate the ideal threshold at which therapy should be initiated, and the extent of correction considered safe and desirable. Two large mortality morbidity trials, TREAT in CKD and RED-HF in HF, are in progress and may be able to provide answers to some of these questions.

Disclosures
Anatole Besarab: consultant to Amgen, Affymax, Roche, Fibrogen (all manufacturers of ESAs) and is on speakers’ board and has received honoraria from Watson Pharma and American Regent Labs.

Michael Hudson: grant support to the Henry Ford Coordinating Center from Scios/Johnson & Johnson, Schering Plough, and deCode Genetics.

References


